抑制炎症因素在他汀类药物心血管疾病多效性中的作用

Statins Pleiotropic Effects on Limit Inflammation Factors of Cardiovascular Disease

他汀类药物自1976年上市应用于临床治疗以来,其非调脂作用,即他汀类药物的多效性近些年来越来越引起人们的重视,尤其是抑制炎症因素方面。随着近些年来研究的不断深入,越来越多的证据表明C反应蛋白作为体内最敏感的炎性标志物之一参与了多种临床常见心血管疾病的发生发展过程。而他汀类药物随着REVERSAL、PROVE IT、MIR-ACL等研究结果的不断公布,能够通过降低C反应蛋白水平抑制炎症因素,从而使患者在心血管疾病临床治疗中获得更大的益处。因此本文将他汀类药物通过抑制炎症因素在心血管疾病治疗中的多效性作用进行分析。

Since 1976 Statins were applied to clinical therapy, beside it lipid--lowering therapy, Statins pleiotropic effects are more and more attracted people＇s attention in recent years. Especially in limit inflammation factors, now many studies confirm that C--reactive protein（CRP） as one of the most sensitive inflammatory markers participate in the processing of cardiovascular disease. While as the REVERSAL, PROVE IT, MIRACL research results published, patients can receive more benefits from Statins therapy by decrease serum CRP level. Therefore we review the Statins pleiotropic effects on cardiovascular disease.